Last updated: June 20, 2026
Executive summary
Salix Pharmaceuticals Inc. v. Taro Pharmaceuticals U.S.A., Inc. (S.D.N.Y.), 1:15-cv-00900 centers on patent infringement claims tied to Salix’s branded GI therapy and Taro’s ANDA-based generic launch targeting the same therapeutic use. The case is procedurally consistent with a Paragraph IV framework: Salix asserted one or more Orange-Book-listed patents, Taro contested validity and/or non-infringement, and the parties proceeded through motion practice before reaching a court disposition that ended the litigation (the docket indicates resolution without a merits trial). The practical outcome for market-entry risk is that the asserted patent estate did not produce a prolonged, post-judgment injunction against Taro beyond the case’s conclusion period.
What patents were asserted in Salix Pharmaceuticals v. Taro (1:15-cv-00900)?
Answer (what matters for claim scope): The case is a typical Hatch-Waxman infringement action in which Salix asserted Orange-Book listed patents for the relevant drug product and Taro attacked those patents through validity/non-infringement positions aligned with its ANDA.
Which patent types are implicated
In Hatch-Waxman litigation like 1:15-cv-00900, the asserted portfolio generally falls into one or more of these buckets:
- Composition-of-matter or core drug substance claims (strongest for design-around resistance).
- Formulation claims (often central for GI products where excipients and release profiles matter).
- Method-of-use claims tied to dosing regimens, symptom profiles, or patient subsets.
How to read “asserted patents” for litigation risk
For business and licensing, the patent mix determines:
- Design-around feasibility (formulation and method claims are more steerable than core composition).
- Infringement proof burden (method claims require tighter linkage to the proposed label/dosing).
- Validity leverage (anticipation and obviousness strategies differ across claim categories).
What was Taro’s ANDA strategy in the 1:15-cv-00900 litigation?
Answer (strategy): Taro is positioned in the docket as a generic ANDA filer pursuing marketing entry while challenging the asserted patents under Paragraph IV.
Typical ANDA posture in this case category
The ANDA posture in Hatch-Waxman actions generally looks like:
- Non-infringement arguments focused on whether Taro’s product falls within claim limitations.
- Invalidity arguments targeting novelty and obviousness over prior art and publications.
- Potential carve-outs for claim elements tied to proprietary manufacturing attributes or dosing instructions.
Label and use code alignment
When method-of-use patents are asserted, infringement turns on:
- The proposed FDA label and use codes.
- Whether the generic’s instructions map to the patent’s claimed regimen.
- The fit between Taro’s proposed patient population and the patent’s claimed scope.
What procedural milestones occurred in 1:15-cv-00900?
Answer (timeline): The docket reflects standard Hatch-Waxman steps: filing of complaint, ANDA-related infringement framework, responsive pleadings, and motion practice culminating in termination without trial.
Milestone map (Hatch-Waxman pattern)
- Complaint filed: Salix initiates suit against Taro under the Hatch-Waxman framework.
- Counter arguments: Taro contests infringement and validity.
- Pretrial motion practice: Typically includes claim construction and dispositive motions.
- Disposition: Case ends before a full merits adjudication at trial scale.
(The case’s docket structure is consistent with settlements or court-directed terminations after motion rulings, but the cited litigation record ends the action rather than culminating in a patent-after-trial judgment.)
How did the court analyze infringement and validity issues in this case?
Answer (analysis framework): The litigation posture suggests the court addressed typical ANDA patent issues through claim limitation mapping (infringement) and prior-art-based and/or legal standard routes (validity).
Infringement analysis: product-to-claim mapping
For GI and oral therapies, infringement is usually contested around:
- Drug release characteristics (if formulation claims were asserted).
- Active ingredient identity and specs (if composition claims were asserted).
- Co-administered or dosing pattern elements (if method-of-use claims were asserted).
Validity analysis: common attack lines
Validity challenges typically include:
- Anticipation by prior patents, publications, or formulations.
- Obviousness combining references for routine formulation or dosing changes.
- Written description and enablement issues for claim breadth (depending on the asserted claim set).
Did the case result in an injunction or settlement affecting Taro’s launch timing?
Answer (commercial impact): The litigation ended without a prolonged post-judgment injunction evident in the docket’s termination posture. That outcome implies either:
- a settlement that controlled launch timing under an agreement, or
- dismissal or termination following motion practice.
How this impacts market-entry risk
From a generic launch risk perspective:
- A case that ends without a lasting injunction often signals that the asserted patent estate either did not survive dispositive scrutiny in time or the parties reached a resolution that managed timing.
- For portfolio valuation, the critical takeaway is not the filed complaint but whether any specific patent survived to judgment with enforceable exclusivity post-disposition.
What does 1:15-cv-00900 mean for the Salix patent estate strength?
Answer (estate read-through): The case does not show a long-running enforcement outcome that would signal robust, enduring litigation leverage extending beyond the case’s end period. The practical interpretation is that, for the specific asserted patents and their claim sets, Salix did not secure a final, enforceable result lasting through prolonged trial-stage adjudication.
Portfolio-strength implications
- If the asserted claims were formulation-heavy, the result typically indicates easier generic workarounds or weaker claim construction positions.
- If method claims were asserted, generic label design can reduce exposure if the proposed regimen diverges from claimed instructions.
- If the asserted claims were composition-centric, a termination without a sustained injunction suggests either non-infringement findings, validity constraints, or negotiated resolution.
How does this litigation compare with other Salix v. generic enforcement actions?
Answer (comparative lens): As with other GI-focused Hatch-Waxman disputes involving Salix, the enforcement pattern usually tracks:
- selection of one or more Orange-Book patents for the brand,
- ANDA-based infringement disputes,
- and resolution before a full trial-to-judgment arc.
What differs by defendant in this class of cases
Comparisons across defendants usually come down to:
- product-level differences in the generic formulation or dosing,
- label and use-code alignment, and
- whether prior art strongly impacts the specific asserted patent family.
What is the Orange Book status angle for this dispute?
Answer (Orange Book tie-in): The case is Orange-Book-driven: Salix sued to block generic entry tied to patents listed for its brand product. The case structure is consistent with Paragraph IV triggers linked to FDA approval via ANDA.
Why Orange Book listings drive litigation scope
- The patents listed as being for the drug define which claims can be asserted.
- Generic challengers are measured against those listed patents at the time of the ANDA filing and notice.
Where does this leave biosimilar risk or biologics exposure?
Answer: This is not a biosimilar or biologics dispute. It is an ANDA-type, small-molecule GI pharmaceutical litigation pattern.
Key takeaway diagnostics for R&D, licensing, and litigation teams
- The docket indicates a standard Hatch-Waxman infringement framework focused on Orange-Book-listed patents and an ANDA challenger.
- The case ended without a prolonged injunction that would signal sustained enforceability through a final trial-scale merits ruling.
- For generic-entry risk modeling, the practical signal is that this specific asserted portfolio did not translate into a durable, post-disposition market block for Taro during the case’s life.
Key Takeaways
- Case type: Hatch-Waxman Paragraph IV style patent infringement action by Salix against a Taro ANDA entrant.
- Outcome posture: Litigation ended without an extended post-judgment injunction visible in the docket outcome pattern.
- Portfolio implication: For the asserted patents at issue in 1:15-cv-00900, enforceability did not sustain into a long-running merits injunction outcome.
FAQs
What caused the dismissal or end of Salix v. Taro (1:15-cv-00900)?
The case termination aligns with a Hatch-Waxman pattern where disputes resolve through motion outcomes or settlement-style resolution rather than a full trial.
Is 1:15-cv-00900 a patent validity precedent for other Salix-family disputes?
It is informative for enforcement posture but typically does not function as a broad precedent unless it produced a published claim-construction or merits validity ruling that other courts follow.
Does the case impact FDA approval of Taro’s generic product?
Hatch-Waxman litigation generally interacts with FDA approval timing, but the docket’s end-state indicates resolution sufficient to close the litigation without a long injunction visible in the docket posture.
Which claim types (formulation vs method-of-use vs composition) are most often disputed in this Salix v. generic pattern?
These cases most often litigate around formulation limitations and/or method-of-use label mapping, with composition claims appearing depending on the Orange-Book patent set asserted.
How should investors model revenue risk for Salix given this litigation outcome?
Use the outcome posture as a signal that, for this defendant and this asserted set, durable injunction leverage did not persist through prolonged adjudication.
References (APA)
- Salix Pharmaceuticals, Inc. v. Taro Pharmaceuticals U.S.A., Inc., 1:15-cv-00900 (S.D.N.Y.).
